银屑病的生物制剂转换。
Biologics switch in psoriasis.
机构信息
Department of Dermatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
Department of Dermatology, Chung Shan Medical University, Taichung, Taiwan.
出版信息
Immunotherapy. 2019 Apr;11(6):531-541. doi: 10.2217/imt-2018-0131.
No guidelines exist for biologic switch in psoriasis after treatment failure. Although, switching between TNF-α antagonists has been reviewed, switching information about newer biologics is limited. We did a thorough systematic review from 'PubMed' and 'Embase', which includes new biologics such as IL-12/IL-23 antagonists, IL-17A antagonists and IL-23 antagonists. New biologics such as IL-17 antagonist or IL-23 antagonist show greater responses in bio-experienced patients and could even be used for patients in whom previous treatments failed.
尚无针对银屑病治疗失败后生物制剂转换的指南。尽管已经对 TNF-α 拮抗剂的转换进行了审查，但关于新型生物制剂的转换信息有限。我们从 'PubMed' 和 'Embase' 进行了全面的系统评价，其中包括新型生物制剂，如 IL-12/IL-23 拮抗剂、IL-17A 拮抗剂和 IL-23 拮抗剂。新型生物制剂，如 IL-17 拮抗剂或 IL-23 拮抗剂，在生物经验丰富的患者中显示出更大的反应，甚至可以用于以前治疗失败的患者。
Zotero 插件